Vivos (RDGL) Cash & Equivalents (2010 - 2025)
Vivos (RDGL) reported Cash & Equivalents of $1.6 million for Q4 2025, down 29.56% on a YoY basis from $2.2 million in Q4 2024, and down 29.23% sequentially from $2.2 million in Q3 2025.
Vivos (RDGL) Cash & Equivalents (2010 - 2025) Analysis & Trends
Vivos (RDGL) has 16 years of Cash & Equivalents data on file, last reported at $1.6 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents fell 29.56% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (down 29.56% YoY), and the FY2025 full-year result was $1.6 million, down 29.56% from the prior year.
- Cash & Equivalents slipped to $1.6 million in Q4 2025, from $2.2 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $3.3 million in Q1 2025 to a low of $1.1 million in Q2 2022.
- A 5-year average of $1.8 million and a median of $1.7 million in 2022 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents surged 13202.47% in 2021 and plunged 51.46% in 2022, its largest moves.
- Tracing RDGL's Cash & Equivalents over 5 years: stood at $1.6 million in 2021, then climbed by 6.22% to $1.7 million in 2022, then retreated by 6.67% to $1.6 million in 2023, then jumped by 38.95% to $2.2 million in 2024, then retreated by 29.56% to $1.6 million in 2025.
- Business Quant data shows RDGL's Cash & Equivalents at $1.6 million in Q4 2025, $2.2 million in Q3 2025, and $2.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 6.80 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 2.88 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.95 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.45 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 2.45 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 1.12 Bn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 2.29 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 557.00 Mn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 3.03 Bn |
| 10 | Vivos | 27.16 Mn | 25.60 Mn | -3,105.00 | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 3.27 Mn |
| Dec 31, 2024 | 2.21 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 1.75 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 1.71 Mn |
| Sep 30, 2022 | 1.99 Mn |
| Jun 30, 2022 | 1.05 Mn |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 1.61 Mn |
| Sep 30, 2021 | 1.99 Mn |
| Jun 30, 2021 | 2.16 Mn |
| Mar 31, 2021 | 2.51 Mn |